Introduction
Three separate mammalian thioredoxin reductases are known. These include widely expressed cytosolic TrxR1, mitochondrial TrxR2, and a third isoform mainly located in testis (1, 2, 3, 4, 5) . All of these enzymes are selenoproteins and carry a selenocysteine (Sec) 1 residue in a carboxyterminal redox active motif having the amino acid sequence -Gly-Cys-Sec-Gly-COOH. The Sec residue in this motif is essential for catalytic activity (2, 6) . Together with the neighboring cysteine it forms a redox active selenenylsulfide / selenolthiol motif (7) that receives electrons from a redox activeCys-Val-Asn-Val-Gly-Cys-motif present in the N-terminal domain of the other subunit in the dimeric holoenzyme (8) . This N-terminal redox active motif is also present in other enzymes of the pyridine nucleotide disulfide oxidoreductase family, such as glutathione reductase and lipoamide dehydrogenase; as in all of these enzymes is this motif receiving electrons from a flavin prosthetic group that in turn is reduced by NADPH (7, 8, 9) .
Beside glutathione reductase (10) , cytosolic TrxR1 is believed to be a most important enzyme for control of the cellular redox state, antioxidant defense and redox 1 Abbreviations used in this study: Sec, selenocysteine; TrxR1, full length Sec-containing thioredoxin reductase 1; truncTrxR1, Sec-deficient two-amino acid truncated TrxR1; rTrxR1, recombinant TrxR1 prepartion; GR, glutathione reductase; GSSG, glutathione disulfide; AIF, apoptosis inducing factor; ASK-1, apoptosis signal regulating kinase 1; DNCB, 1-chloro-2,4,-dinitrobenzene; dnpTrxR1, dinitrophenyl-derivatized rTrxR1 made by reaction with DNCB; CDDP or cisplatin, cisdiamminedichloroplatinum (II); CDDP-TrxR1, rTrxR1 derivatized by reaction with CDDP; IFN-ß, interferon-ß by guest on http://www.jbc.org/
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-4 -regulation of cellular processes. These diverse functions mainly derive from cellular actions by its main substrate, thioredoxin 1 (Trx1) that has a remarkable range of cellular activities (11, 12) . A main function of TrxR1 is hence to reduce Trx1 and many of the intracellular functions held by reduced Trx1 are known to promote cell viability.
Among these functions are inhibition of apoptosis signal regulating kinase 1 (13) , regeneration of peroxiredoxins (14) and methionine sulfoxide reductase (15) , with the latter enzymes playing central roles for cell (16) and organism (17) survival or ageing.
Moreover, TrxR1 is readily inhibited by a number of electrophilic agents used as anticancer agents in clinical use, including quinones (18, 19) and cisplatin (20, 21) , and the drug auranofin that is used against rheumatic disorders (22) . The potential importance of TrxR1 as a clinical drug target was recently reviewed (23) .
In light of such studies as those referred to above, that all in essence identify the selenium-dependent TrxR1 and the thioredoxin system as important for normal cell function and viability, it is most interesting that TrxR1 has also been shown to function as a cell death promoting factor. A Gene associated with Retinoid-Interferon-induced Mortality (GRIM-12), subsequently shown to be TrxR1, was reported to mediate the cell death effects seen in tumor cell lines treated with a combination of IFN-ß and alltrans-retinoic acid (24) . The identification of GRIM-12 was elegantly made by use of an antisense cDNA library expressed under control of an interferon-induced promoter in HeLa cells, screened for induced resistance to retinoid-and interferon-induced cell death, cloned in E. coli and subsequently ascertained for protective effects when transfected into MCF-7 cells (24) . Thus, antisense TrxR1 cDNA expression protected MCF-7 cells from cell death induced by the retinoid-interferon combination, suggesting that TrxR1 activity was a prerequisite for the cell death effect. Subsequent studies clearly indicated that the cell death was apoptotic, dependent upon wild type Trx1 and involved both caspase-8 and p53 (25, 26, 27) . A link between Trx1 and p53 was known by guest on http://www.jbc.org/
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Selenium compromised TrxR1 is a cell death factor -5 -previously (28) and GRIM-12/TrxR1 was shown to be a prerequisite for retinoid/interferon-induced cell death, but notably not for cell death induced by TNFα, etoposide or vincristine (24) . This reflects a need for a functional thioredoxin system in induction of apoptosis through p53 upon treatment of cells specifically with the retinoid/interferon combination (24).
We were, however, intrigued by the fact that transient transfection with TrxR1 constructs were shown to directly induce cell death in MCF-7 cells, with 25% cell death 72 hours post-transfection compared to 8% in vector controls (27) or, in a subsequent study, up to 40% cell death 40 hours post-transfection with similar results in T47D, COS-7 and HeLa cells (29) . How could this selenoprotein, hitherto considered essential for cell viability, display such potent cell death-promoting effects? Considering the well known inefficiency in the mammalian selenoprotein translation machinery, which also has been demonstrated using transfection constructs for TrxR1 (30), we hypothesized that these cell death-promoting effects of TrxR1 might have been due to the formation of truncated selenium-deficient protein species. This assumption was corroborated by the fact that the Selenocysteine Insertion Sequence (SECIS) element in the 3'-untranslated region, necessary for TrxR1 selenoprotein production (2, 30), had not been included in the constructs directly promoting cell death (27, 29) . Furthermore, selenocysteine in TrxR1 is as in all selenoproteins co-translationally inserted at a UGA codon, which normally confers termination of translation (1, 2, 30, 31) . In case of GRIM-12, this UGA codon was initially interpreted as a termination codon and replaced with a nucleotide sequence encoding a c-myc tag (24) . That construct has, nonetheless, subsequently been utilized for transfection studies with results interpreted to show that "wild type" thioredoxin reductase may induce cell death (27, 29, 32) . In an attempt to scrutinize whether the direct deleterious effects by TrxR1 on cell viability could specifically be attributed to selenium compromised forms of TrxR1, we have here by guest on http://www.jbc.org/
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Selenium compromised TrxR1 is a cell death factor -6 -made use of a recently developed methodology for lipid-mediated delivery of intact proteins into mammalian cells (33) . This approach was chosen to avoid any production of a mixture of full-length and truncated TrxR1 that may result from inefficient selenoprotein synthesis using transfection experiments, even using constructs including the selenocysteine-encoding UGA codon and a correct mammalian SECIS element. As reported herein, we found that selenium compromised TrxR1, either a seleniumdeficient truncated form or an enzyme derivatized at the selenocysteine residue, indeed rapidly induced cell death, whereas such direct effect on viability could not be seen using the full-length selenocysteine-containing enzymatically active form of the enzyme. 
Experimental Procedures
Chemicals and reagents
BioPORTER
Preparation of different forms of recombinant TrxR1
Recombinant selenocysteine containing TrxR1 (rTrxR1) was purified from an overproducing E. coli system as described previously (34) 
Enzymatic assays
TrxR1 activities of different preparations were determined using the standard DTNB assay (36) . NADPH oxidase activity was determined as described previously (35) by following A 340 in a reaction mixture with 500 µl 50 mM Tris-Cl, pH 7.5, 2 mM EDTA and 200 µM NADPH using 2.55 µM enzyme. The activity of GR was determined following the initial linear decrease of A 340 in a 500 µl reaction mixture containing 50 mM Tris-Cl, pH 7.5, 2 mM EDTA, 200 µM NADPH and 2 mM GSSG.
The NADPH oxidase activity of GR was determined according to the same protocol as for TrxR1.
Cell cultures and BioPORTER experiments
A549 (human lung carcinoma) cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% heat inactivated fetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin in an humidified atmosphere of 5% CO 2 and 95% air at 37°C. Cells were seeded in LabTec II chamber slides (0.7 cm 2 /well) (Nunc, Denmark) 24 hours before incubation with BioPORTER, which was prepared according to the manufactures protocol, shortly described as follows.
Chloroform (250 µl) was used to dissolve the dried BioPORTER reagent present in one tube as delivered (catalog number BP502401, Gene Therapy Systems), which was 
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Selenium compromised TrxR1 is a cell death factor -9 -volume of 250 µl. This medium preparation with BioPORTER/TrxR1 was added to the cells grown in chamber slides (10,000 cells per well), which had first been washed once with serum free media. Cells were subsequently incubated 4 hours at 37°C before microscopy assessment.
Microscopy and assessment of cell viability
The cells were washed three times with PBS prior to microscopy with a power Leica DMRB microscope equipped with Fluotar PL 10X and Fluotar PL 20X objectives with filters for DAPI, Rhodamine and FITC. A Hamamatsu digital camera 4742-95 was used to obtain the microscopic images. Cells treated with 5-IAF-TrxR1 were subjected to bright field and FITC-filtered images, whereas assessment of viability was performed with bright field, DAPI (for Hoechst staining) and Rhodamine (for propidium iodide staining) filters. For staining, the cells washed in PBS were first incubated for 15 minutes 20°C with Hoechst 33342 dye (5 µg/ml in PBS) whereupon propidium iodide was added (50 µg/ml from 5 mg/ml stock in PBS) and then cells were incubated for an additional period of 5 minutes. Cell morphology was assessed as follows: Viable cells were considered to have Hoechst-stained normal-sized smooth nuclei without red propidium iodide staining, while cells having red stained nuclei with either multiple bright specks of fragmented chromatin or one or more spheres of condensed chromatin with more compact nuclei than normal were judged to be apoptotic, whereas necrotic cells had red-stained smooth nuclei of roughly the same size as viable cells.
Results
The aim of this study was to introduce different forms of TrxR1 into mammalian cells and study effects on cell viability. As mentioned in the Introduction, use of a novel lipid-mediated delivery system (33) 
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-10 -opens a possibility to study isolated effects of the selenium-containing compared to selenium-compromised forms of TrxR1. We wished to introduce into cells a) fully active selenocysteine containing TrxR1, b) truncated selenocysteine-deficient TrxR1 and c) TrxR1 derivatized with DNCB. The latter yields an enzyme devoid of the Trx1-reducing capacity but with an increased NADPH oxidase activity, producing superoxide (35) . Furthermore, we also utilized TrxR1 derivatized with the clinically used antitumor agent cisplatin, which inhibits TrxR1 activity but does not induce its inherent NADPH oxidase activity (20) . In order to have well-defined preparations of TrxR1 we made use of purified recombinant enzyme produced in E. coli either using a system tailored for heterologous production of the full-length selenoprotein or a construct without a SECIS element, thereby producing the two-amino acid truncated selenium deficient form of the enzyme (34) . However, the system for production of recombinant selenoprotein results in a mixture of truncated and full-length enzyme (34). Therefore we have further isolated the full-length recombinant TrxR1 from the purified preparation, as described in Experimental Procedures. We also used the original preparation of rTrxR1 containing a mixture of full-length and truncated enzyme species. Furthermore, we analyzed effects of GR that is a non-selenoprotein enzyme closely related to mammalian TrxR1 in both structure (8) and primary sequence (2) but naturally lacking the C-terminal Sec-containing redox active center (2,7). We also found GR to have a greater inherent NADPH oxidase activity than TrxR1. The properties of the enzyme preparations used in this study are summarized in Table 1 .
The BioPORTER technique has been shown to successfully introduce antibodies, dextran sulfates, phycobiliproteins, albumin, and functional enzymes like betagalactosidase and caspases into living cells (33) . However, it could not be used to introduce apoptosis-inducing cytochrome c (33), which contrasts the introduction into cells of cytochrome c using microinjection techniques (37) . Therefore, we first used We next analyzed if TrxR1 derivatized with cisplatin could induce cell death in a manner similar to truncated or dinitrophenyl derivatized TrxR1, which indeed was the case ( Figure 4A ). This suggested that the NADPH oxidase activity of the derivatized enzyme seemed not to be an essential factor for the cell death induction, since truncated TrxR1 or CDDP-TrxR1, in contrast to dnp-TrxR1, lacked a significant increase in the inherent NADPH oxidase activity (Table I) . We also analyzed the effects of a glutathione reductase preparation that had higher inherent NADPH oxidase activity than (Table I) . We found no induction of cell death using this glutathione reductase ( Figure 4B ).
Discussion
The studies presented here show that truncated selenium deficient TrxR1, or forms of the enzyme compromised at the selenocysteine residue with either cisplatin or dinitrophenyl moieties, may rapidly induce cell death. The enzymatically active full length enzyme did not hold this property. Remarkably, the only difference between truncated and full length TrxR1 protein is the presence in the latter of the two final carboxyterminal amino acids (-Sec-Gly-COOH). In case of truncated TrxR1, and also CDDP-TrxR1, use of BioPORTER was needed for cell death to be provoked which demonstrated that the cell death-promoting actions of these TrxR1 derivatives were intracellular (Figures 3 and 4A) . The dinitrophenyl-derivatized enzyme gave a similar induction of cell death in the presence of BioPORTER, but there was also a certain induction of cell death by dinitrophenyl-derivatized TrxR1 in the absence of lipid reagent (Figure 3 ). This may possibly suggest that extracellularly, dinitrophenylderivatized TrxR1 can have access to reducing equivalents, perhaps by interaction with other reductive proteins at the cell surface, so that its increased oxidase activity (Table   I ) producing superoxide (35) , may also induce cell death when present on the outside of cells. Glutathione reductase with a higher NADPH oxidase activity (Table I) What is the mechanism for cell death induced by different forms of TrxR1? From the published GRIM-12 studies, it seems clear that an intact thioredoxin system is a prerequisite for a functional apoptotic machinery upon treatment of cells with a retinoid-interferon combination (24) . The importance for an intact functional TrxR1/Trx system in induction of apoptosis after the retinoid-interferon combination clearly involved p53 modulation and caspase-8 activation (26, 27, 29, 43 ). The necessity of intact TrxR1 for p53 maturation was recently also demonstrated in a separate study showing derivatization of the selenocysteine in TrxR1 by electrophilic lipid derivatives, resulting in impaired maturation and function of p53 (44) . The direct cell deathpromoting effects of wild type TrxR1 that were proposed (27) , however, were questionable to us and were the reason for the design of the here presented study. Since the transient transfection experiments with "wild type" GRIM-12/TrxR1 shown to directly promote cell death (27, 29) in fact involved production of truncated TrxR1 (see the Introduction), some is already known about the death-promoting effects of truncated TrxR1. It seems that a preserved N-terminal redox active -Cys-Val-Asn-Val-Gly-Cysmotif is a prerequisite, because when this motif was replaced by a dipeptide -Gly-Alamotif, the cell death-promoting effect was lost (29) . Moreover, removal of the whole interface domain of TrxR1, i.e. the C-terminal third of the protein (2) governing subunit association (8) , resulted in even further increased cell death-promoting effects as compared to solely truncated TrxR1 -called "wild-type" in (27, 29) -while both the FAD and NADPH-binding domains (2, 8) were necessary to maintain in order to have a direct cell death-promoting effect (43) .
It could be hypothesized that selenium compromised TrxR1 can interact with the endogenous selenium dependent thioredoxin system by formation of mixed complexes with endogenous Trx1 or TrxR1 subunits. If the endogenous thioredoxin system indeed would be inhibited in a dominant manner, apoptosis may be provoked both due to a reduced general antioxidant defense as well as direct activation of ASK-1, as proposed to be the possible downstream effects of general TrxR1 inhibition (12, 23) . However, 
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-17 -and p53-mediated cell death (28, 44) requires an additional stimulus activating p53 for cell death execution to occur and is hence an alternative pathway in which the thioredoxin system is involved in apoptosis. Furthermore, the inhibition of ASK-1 and thereby inhibition of apoptosis by reduced thioredoxin (13) as well as antiapoptotic functions of peroxiredoxins being dependent on a functional thioredoxin system (16) result in a delicate balance between promotion of cell viability and induction of apoptosis, regarding effects mediated by the thioredoxin system. The different pathways for cell viability promotion or apoptosis induction that are affected by the status of the thioredoxin system are summarized in Figure 5 . Further studies on the direct cell-death promoting effects of selenium compromised TrxR1 are certainly warranted and necessary to consider as an additional pathway for induction of apoptosis. a Specific activities of TrxR1 derivatives were determined using the classical DTNB assay, in which native enzyme homogeneously purified from mammalian tissues displays an activity of approx. 35 U/mg (36) . The specific activity of GR was determined with 2 mM GSSG and 200 µM NADPH at pH 7.5, as described in Experimental Procedures.
b The NADPH oxidase activity was determined as described previously (35) and in Experimental Procedures.
c The rTrxR1 as purified from the bacterial production system is a mixture of fulllength TrxR1 and truncated enzyme, with the Se content estimated from the specific activity. For further details, see (34) .
d Dinitrophenyl derivatization was performed with DNCB as described (35) using a preparation of rTrxR1 with 7 U/mg original specific activity as enzyme source.
e CDDP derivatization was performed as described (20) analyzed for viability and evaluated as described in the legend of figures 2 and 3. The CDDP control shows the effects of a control sample treated identically to "CDDPTrxR1", except that no enzyme had been added in the original sample. In B), an experiment comparing the effects of truncTrxR1 with fully active GR (see Table I ) is shown. * = p < 0.01; ** = p < 0.005; n = 4 for each treatment in both A and B. by guest on 
